Patents Represented by Attorney Arnold & Porter LLP
  • Patent number: 8163287
    Abstract: The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: April 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Mark X. Sliwkowski, Stephen M. Kelsey
  • Patent number: 8158762
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: April 17, 2012
    Assignee: Genentech, Inc.
    Inventors: Menno Van Lookeren Campagne, Laura Deforge
  • Patent number: 8147827
    Abstract: The invention concerns an improved method for treating tumor, including cancer, which combines the administration of a chemotherapeutic agent and an antagonist of a gene product the expression of which is upregulated by the chemotherapeutic agent. The invention further concerns methods and means for the diagnosis and classification of tumors, and for the prognosis of the outcome of tumor treatment, and patient response to a particular treatment modality.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: April 3, 2012
    Assignee: Genentech, Inc.
    Inventor: Paul Polakis
  • Patent number: 8147830
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: April 3, 2012
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Patent number: 8148085
    Abstract: The present invention concerns donor-specific antibody libraries derived from a patient donor who has suffered from, or is suffering from one or more diseases discussed herein. The present invention also concerns the method of making and using the donor-specific antibodies. The present invention further concerns the neutralizing antibodies obtained from the donor-specific antibody libraries and the methods of using these antibodies for the prevention/treatment of human disease.
    Type: Grant
    Filed: September 11, 2007
    Date of Patent: April 3, 2012
    Assignee: Sea Lane Biotechnologies, LLC
    Inventors: Lawrence Horowitz, Ramesh Bhatt, Arun K. Kashyap
  • Patent number: 8143039
    Abstract: The present invention provides a method and compositions for high throughput screening of genetically modified photosynthetic organisms for plasmic state. The present invention provides methods of producing one or more proteins, including biomass degrading enzymes in a plant. Also provided are the methods of producing biomass degradation pathways in alga cells, particularly in the chloroplast. Single enzymes or multiple enzymes may be produced by the methods disclosed. The methods disclosed herein allow for the production of biofuel, including ethanol.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: March 27, 2012
    Assignees: Sapphire Energy, Inc., The Scripps Research Institute
    Inventors: Stephen Mayfield, Bryan O'Neill, Michael Mendez, Yan Poon
  • Patent number: 8144151
    Abstract: Complex events for an entity are gathered, each including an event, the event's location, and the date of the event. A map encompassing the locations of the complex events is displayed. The location of each complex event is denoted on the map, such as by an icon corresponding to the complex event type, in a color corresponding to whether the complex event was validated. For each successive pair of complex events, including a first and a second complex event, a line is drawn on the map between their locations. Timelines graphically denoting the complex events in order of their dates may be displayed, including one corresponding to those complex events that have been validated, and others that each correspond to those complex events that come from the same source. A list of the complex events may be displayed, organized in accordance with the types of the complex events.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: March 27, 2012
    Assignee: HireRight, Inc.
    Inventors: Stefano Malnati, Aleksandr Rudenko, Andrel Zhovjev, Jeff Davis
  • Patent number: 8137671
    Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: March 20, 2012
    Assignee: Genentech, Inc.
    Inventors: Krzysztof Masternak, Francois Rousseau
  • Patent number: 8131480
    Abstract: The present invention concerns the design and construction of diverse peptide and polypeptide libraries. In particular, the invention concerns methods of analytical database design for creating datasets using multiple relevant parameters as filters, and methods for generating sequence diversity by directed multisyntheses oligonucleotide synthesis. The present methods enable the reduction of large complex annotated databases to simpler datasets of related sequences, based upon relevant single or multiple key parameters that can be individually directly defined. The methods further enable the creation of diverse libraries based on this approach, using multisynthetic collections of discrete and degenerate oligonucleotides to capture the diverse collection of sequences, or portions thereof.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: March 6, 2012
    Assignee: Sea Lane Biotechnologies LLC
    Inventors: Lawrence Horowitz, Ramesh Bhatt, Aaron L. Kurtzman
  • Patent number: 8124844
    Abstract: Polynucleotides useful for improvement of plants are provided. In particular, polynucleotide sequences are provided from plant sources. Polypeptides encoded by the polynucleotide sequences are also provided. The disclosed polynucleotides and polypeptides find use in production of transgenic plants to produce plants having improved properties.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: February 28, 2012
    Assignee: Monsanto Technology LLC
    Inventors: Thomas J. La Rosa, David K. Kovalic, Yihua Zhou, Yongwei Cao, Mark S. Abad, Scott E. Andersen, Robert E. Buehler, Joseph R. Byrum, Nordine Cheikh, Timothy W. Conner, Brian E. Coombs, Stanton B. Dotson, Patrice Dubois, Michael D. Edgerton, Dane K. Fisher, Kristine J. Hardeman, Gregory J. Heck, Gregory J. Hinkle, Raghunath V. Lalgudi, Jingdong Liu, Linda L. Lutfiyya, Debbie A. Mahadeo, James D. Masucci, James D. McIninch, Philip W. Miller, Donald E. Nelson, Ming Peng, Thomas G. Ruff, Hridayabhiranjan Shukla, Joshua Stein, Michael D. Thompson, Kunsheng Wu
  • Patent number: 8114967
    Abstract: The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chain variable domain sequences, and libraries containing the same.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: February 14, 2012
    Assignee: Sea Lane Biotechnologies LLC
    Inventors: Ramesh Bhatt, Lawrence Horowitz, Li Xu
  • Patent number: 8110548
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: February 7, 2012
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C. A. F. Robinson, Nicholas J. Skelton
  • Patent number: 8107693
    Abstract: The present invention provides a complete artificial intelligence system for the acquisition and analysis of nucleic acid array hybridization information. The system includes a central data processing facility and one or more user facilities, linked by encrypted connections. Each user facility may include an optical scanning system to collect hybridization signals from a nucleic acid array, an image processing system to convert the optical data into a set of hybridization parameters, a connection to a data network, and a user interface to display, manipulate, search, and analyze hybridization information. This system reads data from a nucleic acid microarray, analyzes test results, evaluates patient risk for various ailments, and recommends methods of treatment. The automated artificial intelligence system is a real time, dynamic decision making tool that can be used in conjunction with a clinical analysis system, and with the information obtained in a research and development environment.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: January 31, 2012
    Assignee: Iris Biotechnologies, Inc.
    Inventors: Glenn F. Osborne, Simon S. M. Chin, Paul McDonald, Scott Schneider
  • Patent number: 8106174
    Abstract: Recombinant polynucleotides and recombinant polypeptides useful for improvement of plants are provided. The disclosed recombinant polynucleotides and recombinant polypeptides find use in production of transgenic plants to produce plants having improved properties.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: January 31, 2012
    Assignee: Monsanto Technology LLC
    Inventors: David K. Kovalic, Yihua Zhou, Yongwei Cao, Scott E. Andersen, Michael D. Edgerton, Jingdong Liu
  • Patent number: 8101571
    Abstract: NGF variants which have trkC-binding activity and trkC-signal inducing activity are provided. The variants optionally have trkA or trkB binding and signal induction activity. The NGF variants of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the NGF variant neurotrophins are also provided.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: January 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Leonard G. Presta, Roman Urfer, John W. Winslow
  • Patent number: 8101817
    Abstract: The present invention relates to an iceberg lettuce having one or more romaine lettuce characteristics. The invention further relates to methods for producing iceberg lettuce varieties containing one or more romaine lettuce characteristics.
    Type: Grant
    Filed: January 5, 2009
    Date of Patent: January 24, 2012
    Assignee: Seminis Vegetable Seeds, Inc.
    Inventor: William Waycott
  • Patent number: 8101827
    Abstract: Inbred broccoli lines, designated BRM50-3906 are disclosed. The invention relates to the seeds of inbred broccoli lines BRM50-3906, to the plants of inbred broccoli lines BRM50-3906, and to methods for producing a broccoli plant produced by crossing the inbred line BRM50-3906 with itself or another broccoli line. The invention further relates to hybrid broccoli seeds and plants produced by crossing the inbred line BRM50-3906 with another broccoli line.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: January 24, 2012
    Assignee: Seminis Vegetable Seeds, Inc.
    Inventors: Franciscus van den Bosch, Meinardus Petrus Boon
  • Patent number: 8097587
    Abstract: IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: January 17, 2012
    Assignee: Genentech, Inc.
    Inventors: Yves Dubaquie, Paul J. Fielder, Henry B. Lowman, Deborah L. Mortensen
  • Patent number: 8097778
    Abstract: The present invention is directed to nucleic acid molecules and nucleic acid constructs, and other agents associated with fatty acid synthesis, particularly the ratios of saturated and unsaturated fats. Moreover, the present invention is directed to plants incorporating such agents where the plants exhibit altered ratios of saturated and unsaturated fats. In particular, the present invention is directed to plants incorporating such agents where the plants exhibit altered ratios of monounsaturated to polyunsaturated fatty acids.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: January 17, 2012
    Assignee: Monsanto Company
    Inventor: Joanne J. Fillatti
  • Patent number: 8088386
    Abstract: The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: January 3, 2012
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Karim Yussef Helmy, Sherman Fong, Audrey Goddard, Austin L. Gurney, Kenneth James Katschke, Jr., Menno Van Lookeren, William I. Wood